Macquarie Upgrades ResMed to Outperform

Macquarie analyst David Bailey upgrades ResMed (NYSE:RMD) from Neutral to Outperform.

byBenzinga Newsdesk

December 6, 2021

1 minute read

Macquarie analyst David Bailey upgrades ResMed (NYSE:RMD) from Neutral to Outperform.

Deluxe Announces Collaboration With Microsoft To Provide HR, Payroll, Accounting Tools For Small Businesses

By Benzinga Newsdesk

June 24, 4:30 PM

from Deluxe with Dynamics 365 Business Central, Deluxe is also creating an innovative partnership with Bam Boom Cloud, a past recipient of Microsoft's Partner of the Year Award for demonstrating excellence in

DLX

North American Construction’s Mikisew North American Limited Reports $125M Backlog Contract Win By ‘Major’ Oil Sands Producer

By Benzinga Newsdesk

March 17, 5:10 PM

North American Construction Group Ltd. (“NACG” or “the Company”) (TSX:NOA, NYSE:NOA) today announced a five-year contract awarded to Mikisew North American Limited Partnership

NOA

FDA
News

Exelixis Announces U.S. FDA Accepts For Priority Review The Supplemental New Drug Application For CABOMETYX For Patients With Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

By Benzinga Newsdesk

August 5, 8:24 AM

Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for CABOMETYX® (cabozantinib) as a treatment for

EXEL

3 Penny Stocks Insiders Are Buying

By Lisa Levin

September 14, 9:39 AM

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

NGL

Macquarie Upgrades ResMed to Outperform

Related Posts

Deluxe Announces Collaboration With Microsoft To Provide HR, Payroll, Accounting Tools For Small Businesses

North American Construction’s Mikisew North American Limited Reports $125M Backlog Contract Win By ‘Major’ Oil Sands Producer

Exelixis Announces U.S. FDA Accepts For Priority Review The Supplemental New Drug Application For CABOMETYX For Patients With Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

3 Penny Stocks Insiders Are Buying